Taken together these results show that therapeutic protein vaccine treatment highly increases HPV-specific CD8 T cells tumor infiltration and functionality and while STINGa monotherapy has no effect, the combination further enhances vaccination efficacy. This evidence concerns the gene CD8A and neoplasm.